Tuesday: FDA panel reviews Merck's Ragwiteck

Share this article:

Merck's prescription allergy medication Ragwitek is going before the FDA Allergenic Products Advisory Committee tomorrow, and the panel's discussion documents indicate the under-the-tongue medication is not associated with serious safety concerns, reports Reuters.

An FDA approval would provide an alternative to injections doctors typically give for pollen and ragweed allergies.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.